CERT Stock Overview
Provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CERT from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Certara, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.66 |
| 52 Week High | US$19.87 |
| 52 Week Low | US$9.41 |
| Beta | 1.52 |
| 1 Month Change | 8.87% |
| 3 Month Change | 4.11% |
| 1 Year Change | -27.71% |
| 3 Year Change | -54.40% |
| 5 Year Change | n/a |
| Change since IPO | -69.38% |
Recent News & Updates
Certara, Inc.'s (NASDAQ:CERT) Share Price Not Quite Adding Up
Jan 11
Is Certara, Inc. (NASDAQ:CERT) Worth US$10.9 Based On Its Intrinsic Value?
Dec 19Certara (NASDAQ:CERT) Is Reinvesting At Lower Rates Of Return
Nov 15Recent updates
Certara, Inc.'s (NASDAQ:CERT) Share Price Not Quite Adding Up
Jan 11Is Certara, Inc. (NASDAQ:CERT) Worth US$10.9 Based On Its Intrinsic Value?
Dec 19Certara (NASDAQ:CERT) Is Reinvesting At Lower Rates Of Return
Nov 15Is Certara, Inc. (NASDAQ:CERT) Potentially Undervalued?
Oct 24Certara (NASDAQ:CERT) Seems To Use Debt Quite Sensibly
Sep 20Certara: Still Awaiting Consistent Growth
Sep 16Certara, Inc. (NASDAQ:CERT) Shares Could Be 35% Above Their Intrinsic Value Estimate
Aug 31There's Reason For Concern Over Certara, Inc.'s (NASDAQ:CERT) Price
Jul 18Certara (NASDAQ:CERT) Is Looking To Continue Growing Its Returns On Capital
Jun 13When Should You Buy Certara, Inc. (NASDAQ:CERT)?
Apr 11Certara, Inc.'s (NASDAQ:CERT) Share Price Could Signal Some Risk
Mar 21Returns Are Gaining Momentum At Certara (NASDAQ:CERT)
Feb 17Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth
Jan 30Calculating The Fair Value Of Certara, Inc. (NASDAQ:CERT)
Dec 07Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)
Oct 31Is It Time To Consider Buying Certara, Inc. (NASDAQ:CERT)?
Sep 17An Intrinsic Calculation For Certara, Inc. (NASDAQ:CERT) Suggests It's 29% Undervalued
Aug 30Certara (NASDAQ:CERT) Shareholders Will Want The ROCE Trajectory To Continue
Aug 03Certara: A Story To Watch
Sep 27Certara to raise capital in secondary stock offering
Aug 12Shareholder Returns
| CERT | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 9.9% | -0.3% | 3.2% |
| 1Y | -27.7% | -3.1% | 24.2% |
Return vs Industry: CERT underperformed the US Healthcare Services industry which returned -3.1% over the past year.
Return vs Market: CERT underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| CERT volatility | |
|---|---|
| CERT Average Weekly Movement | 6.8% |
| Healthcare Services Industry Average Movement | 9.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CERT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CERT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,365 | Bill Feehery | www.certara.com |
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions.
Certara, Inc. Fundamentals Summary
| CERT fundamental statistics | |
|---|---|
| Market cap | US$1.88b |
| Earnings (TTM) | -US$31.08m |
| Revenue (TTM) | US$372.80m |
5.0x
P/S Ratio-60.4x
P/E RatioIs CERT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CERT income statement (TTM) | |
|---|---|
| Revenue | US$372.80m |
| Cost of Revenue | US$150.32m |
| Gross Profit | US$222.48m |
| Other Expenses | US$253.56m |
| Earnings | -US$31.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 59.68% |
| Net Profit Margin | -8.34% |
| Debt/Equity Ratio | 28.1% |
How did CERT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/19 09:26 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Certara, Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Vruwink | Baird |
| Luke Sergott | Barclays |
| Andrew Moss | BofA Global Research |